Nathanael S. Gray is a Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana-Farber Cancer Institute. Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego (board member). C4 Therapeutics, which offered IPO in 2020, was founded based on the ground-breaking research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gra
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Nathanael Gray (de)
- Nathanael Gray (en)
|
rdfs:comment
| - Nathanael S. Gray ist ein Biochemiker und Molekularbiologe an der Stanford University. (de)
- Nathanael S. Gray is a Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana-Farber Cancer Institute. Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego (board member). C4 Therapeutics, which offered IPO in 2020, was founded based on the ground-breaking research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gra (en)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
workplaces
| - Harvard Medical School (en)
- Stanford University (en)
- (en)
- Dana-Farber Cancer Institute (en)
- Genomics Institute of the Novartis Research Foundation (en)
|
dbp:wikiPageUsesTemplate
| |
alma mater
| |
has abstract
| - Nathanael S. Gray ist ein Biochemiker und Molekularbiologe an der Stanford University. (de)
- Nathanael S. Gray is a Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana-Farber Cancer Institute. Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego (board member). C4 Therapeutics, which offered IPO in 2020, was founded based on the ground-breaking research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gray, while he was professor at Harvard Medical School. Before moving to Stanford University, Nathanael S. Gray created Center for Protein Degradation at Harvard Medical School with $80 million agreement with Deerfield Management venture capital firm. In 2020, Gray Lab permanently moved to Stanford University, that was stated by Stuart Schreiber, co-founder of Broad Institute as "Stanford's huge gain". (en)
|
institution
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
alma mater
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage redirect
of | |
is Wikipage disambiguates
of | |
is notable students
of | |
is notable student
of | |
is foaf:primaryTopic
of | |